Systems, devices, and methods including infection-fighting and monitoring shunts

• US 8,888,731 B2
• Filed: 05/21/2010
• Issued: 11/18/2014
• Est. Priority Date: 08/17/2007
• Status: Expired due to Fees

• Current Assignee: Gearbox LLC (Intellectual Ventures LLC)
• Original Assignee: The Invention Science Fund I, L.L.C. (Intellectual Ventures LLC)
• Inventors: Dacey, Ralph G. Jr., Hyde, Roderick A., Ishikawa, Muriel Y., Kare, Jordin T., Leuthardt, Eric C., Myhrvold, Nathan P., Rivet, Dennis J., Smith, Michael A., Sweeney, Elizabeth A., Tegreene, Clarence T., Wood, Lowell L. Jr., Wood, Victoria Y. H.
• Primary Examiner(s): DEAK, LESLIE R
• Application Number:
  US12/800,792
• Publication Number:
  US 20100241054A1
• Time in Patent Office: 1,642 Days
• Field of Search: 604/6.08, 604/8, 604/9, 604/20
• US Class Current: 604/8
• CPC Class Codes: A61B 18/20 using laser
• CPC Class Codes: A61B 5/0084 for introduction into the body, e.g. by catheters A61B5/1459 takes precedence
• CPC Class Codes: A61B 5/053 Measuring electrical impedance or conductance of a portion of the body
• CPC Class Codes: A61B 5/145 Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissuemeasuring of blood pressure or blood flow A61B5/02; non-radiation detecting or locating of foreign bodies in blood A61B5/06
• CPC Class Codes: A61B 5/14503 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14539 for measuring pH
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence
• CPC Class Codes: A61B 5/1473 invasive, e.g. introduced into the body by a catheter A61B5/1482 takes precedence
• CPC Class Codes: A61B 5/412 Detecting or monitoring sepsis
• CPC Class Codes: A61L 2/0011 using physical methods
• CPC Class Codes: A61L 2/08 Radiation
• CPC Class Codes: A61L 2/14 Plasma, i.e. ionised gases
• CPC Class Codes: A61L 2202/24 Medical instruments, e.g. endoscopes, catheters, sharps
• CPC Class Codes: A61M 27/006 Cerebrospinal drainage; Accessories therefor, e.g. valves
• CPC Class Codes: A61M 5/14276 specially adapted for implantation
• CPC Class Codes: A61N 1/205 for promoting a biological process
• CPC Class Codes: A61N 1/37252 Details of algorithms or data aspects of communication system, e.g. handshaking, transmitting specific data or segmenting data
• CPC Class Codes: A61N 1/3785 generated by biological activity or substance, e.g. body movement
• CPC Class Codes: A61N 1/3787 : from an external energy source
• CPC Class Codes: A61N 1/40 : Applying electric fields by inductive or capacitive coupling microwave apparatus A61N5/00; Applying radio-frequency signals
• CPC Class Codes: A61N 1/403 : for thermotherapy, e.g. hyperthermia
• CPC Class Codes: A61N 2005/0651 : Diodes
• CPC Class Codes: A61N 2005/0652 : Arrays of diodes
• CPC Class Codes: A61N 2005/0661 : ultraviolet
• CPC Class Codes: A61N 5/02 : using microwaves
• CPC Class Codes: A61N 5/0601 : Apparatus for use inside the body
• CPC Class Codes: A61N 5/0624 : for eliminating microbes, germs, bacteria on or in the body
• CPC Class Codes: A61N 5/10 : X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy A61N5/01 takes precedence
• CPC Class Codes: A61N 7/00 : Ultrasound therapy lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 ; using ultrasound for introducing media into the body A61M37/0092

Abstract

Systems, devices, methods, and compositions are described for providing an actively controllable shunt configured to, for example, monitor, treat, or prevent an infection.

Claims

1. An implantable shunt system, comprising:

a body structure having an outer surface and an inner surface defining one or more fluid-flow passageways configured to receive a cerebrospinal fluid of a biological subject; and

one or more energy emitters configured to direct an energy stimulus to at least one of an interior and an exterior of at least one of the one or more fluid-flow passageways, the energy stimulus of a character and for a duration sufficient to induce programmed cell death of at least a portion of cells, without substantially inducing necrosis of at least a portion of cells, proximate at least one of the outer surface and the inner surface of the body structure.

2. The implantable shunt system of claim 1, wherein the body structure includes one or more proximal shunts, distal shunts, or flow-regulating devices, the one or more fluid-flow passageways extending through an interior of the one or more proximal shunts, distal shunts, or flow-regulating devices.

3. The implantable shunt system of claim 1, wherein the body structure includes an inlet and an outlet, at least one of the one or more fluid-flow passageways extending through the body structure between the inlet and outlet.

4. The implantable shunt system of claim 1, wherein at least one of the one or more energy emitters is photonically coupleable to an interior of one or more of the one or more fluid-flow passageways.

5. The implantable shunt system of claim 1, wherein at least one of the one or more energy emitters is photonically coupleable to an exterior of one or more of the one or more fluid-flow passageways.

6. The implantable shunt system of claim 1, wherein at least one of the one or more energy emitters is photonically coupleable, via one or more waveguides, to an interior of at least one of the one or more fluid-flow passageways.

7. The implantable shunt system of claim 1, wherein at least one of the one or more energy emitters is configured to emit an energy stimulus from an interior of at least one of the one or more fluid-flow passageways to an exterior of at least one of the one or more fluid-flow passageways.

8. The implantable shunt system of claim 1, wherein at least a portion of a body structure defining the one or more fluid-flow passageways includes an optical material that permits the transmission of at least a portion of an emitted energy′

stimulus from an interior of at least one of the one or more fluid-flow passageways to an exterior of at least one of the one or more fluid-flow passageways.

9. The implantable shunt system of claim 1, wherein the one or more energy emitters are configured to emit an energy stimulus having one or more peak emission wavelengths in the x-ray, ultraviolet, visible, infrared, near infrared, terahertz, microwave, or radio frequency spectrum.

10. The implantable shunt system of claim 1, wherein at least one of the one or more energy emitters is configured to deliver one or more charged particles.

11. The implantable shunt system of claim 1, wherein the one or more energy emitters include one or more lasers, laser diodes, light-emitting diodes, arc flashlamps, incandescent emitters, or continuous wave bulbs.

12. The implantable shunt system of claim 1, wherein the one or more energy emitters include one or more light-emitting diodes, quantum dots, organic light-emitting diodes, microcavity light-emitting diodes, or polymer light-emitting diodes.

13. The implantable shunt system of claim 1, wherein the one or more energy emitters are configured to provide a voltage across at least a portion of cells within a cerebrospinal fluid received within at least one of the one or more fluid-flow passageways, the voltage of sufficient strength or duration so as to exceed a nominal dielectric strength of at least one cell plasma membrane.

14. The implantable shunt system of claim 1, wherein the one or more energy emitters are configured to provide a voltage across at least a portion of cells within a cerebrospinal fluid received within at least one of the one or more fluid-flow passageways, the voltage of sufficient strength or duration so as to exceed a nominal dielectric strength of a cell plasma membrane without substantially interfering with a normal operation of the implantable shunt system.

15. The implantable shunt system of claim 1, wherein at least a portion of the body structure is configured to sufficiently internally reflect at least a portion of an emitted energy stimulus to generate an evanescent electromagnetic field across one or more regions of the body structure.

16. The implantable shunt system of claim 1, wherein at least a portion of the body structure is configured to sufficiently internally reflect at least a portion of an emitted energy stimulus to cause an evanescent electromagnetic field to emanate from at least a portion of the body structure.

17. The implantable shunt system of claim 1, wherein at least a portion of the body structure is configured to internally reflect at least a portion of an emitted energy stimulus within an interior of at least one of the one or more fluid-flow passageways.

18. The implantable shunt system of claim 1, wherein at least a portion of the body structure is configured to totally internally reflect at least a portion of an emitted energy stimulus propagated within an interior of at least one of the one or more fluid-flow passageways.

19. The implantable shunt system of claim 1, further comprising:

a plurality of electromagnetic energy waveguides operably coupled to the at least one of the one or more energy emitters and configured to direct an emitted energy stimulus to one or more regions proximate at least one of the outer surface and the inner surface of the body structure.

20. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to provide a spatially patterned energy stimulus.

21. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to deliver a spatially collimated energy stimulus.

22. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to deliver a spatially focused energy stimulus.

23. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to provide a temporally patterned energy stimulus.

24. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to deliver an energy stimulus of a character and for a duration sufficient to provide a spatially patterned energy stimulus to one or more regions proximate at least one of the outer surface and the inner surface of the body structure.

25. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to internally direct at least a portion of an emitted energy stimulus propagated within an interior of at least one of the one or more fluid-flow passageways.

26. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to laterally internally direct or longitudinally internally direct at least a portion of an emitted energy stimulus within an interior of at least one of the one or more fluid-flow passageways.

27. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to direct a first portion of an emitted energy stimulus along a substantially lateral direction in one or more regions of at least one of the one or more fluid-flow passageways and configured to direct a second portion of the emitted energy stimulus along a substantially longitudinal direction in one or more regions of at least one of the one or more fluid-flow passageways.

28. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to direct at least a portion of an emitted energy stimulus along a substantially lateral direction in a first region of at least one of the one or more fluid-flow passageways and configured to direct at least a portion of the emitted energy stimulus along a substantially lateral direction in a second region of the one or more fluid-flow passageways, the second region different from the first region.

29. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to direct at least a portion of an emitted energy stimulus along a substantially longitudinal direction in a first region of at least one of the one or more fluid-flow passageways and configured to direct at least a portion of the emitted energy stimulus along a substantially longitudinal direction in a second region of the one or more fluid-flow passageways, the second region different from the first region.

30. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to externally direct at least a portion of an emitted energy stimulus propagated within.

31. The implantable shunt system of claim 19, wherein the plurality of electromagnetic energy waveguides are configured to externally direct at least a portion of an emitted energy stimulus propagated within one or more regions proximate at least one of the outer surface and the inner surface of the body structure.

32. An in vivo method of treating an infectious agent, comprising:

providing an energy stimulus for a time and amount sufficient to induce programmed cell death of an infectious agent, without substantially inducing necrosis of at least a portion of cells, within a cerebrospinal fluid of a mammal, the cerebrospinal fluid received within one or more fluid-flow passageways of an indwelling implant including one or more energy-emitting components energetically coupleable to an interior of the one or more fluid-flow passageways.

33. The method of claim 32, wherein providing the sufficient amount of the energy stimulus includes providing a sufficient amount of at least one of an x-ray, ultraviolet, visible, infrared, near infrared, terahertz, microwave, and radio frequency radiation.

34. The method of claim 32, wherein providing the sufficient amount of the energy stimulus includes delivering an effective dose of optical energy at which a cell preferentially undergoes apoptosis compared to necrosis.

35. The method of claim 32, wherein providing the sufficient amount of the energy stimulus includes providing an ultraviolet radiation of a character or duration to induce cell death by apoptosis.

36. The method of claim 32, wherein providing the sufficient amount of the energy stimulus includes providing a dose of an ultraviolet radiation based on a detected characteristic associated with the cerebrospinal fluid.

37. The method of claim 32, wherein providing the sufficient amount of the energy stimulus includes providing an electromagnetic energy stimulus of a character and for a sufficient time to induce apoptosis without substantially inducing necrosis of an infectious agent present in the cerebrospinal fluid.

38. The method of claim 32, further comprising:

delivering an antimicrobial agent composition to a cerebrospinal fluid received within at least one of the one or more fluid-flow passageways.

39. The method of claim 32, further comprising:

delivering an antimicrobial agent composition to a cerebrospinal fluid received within at least one of the one or more fluid-flow passageways at a dose sufficient to attenuate an activity of the infectious agent.

40. A method of inhibiting a microbial proliferation in the cerebrospinal fluid of a biological subject, comprising:

selectively energizing one or more regions of at least one fluid-flow passageway of an indwelling implant cerebrospinal fluid management system for a time and amount sufficient to induce programmed cell death of a microbe via one or more energy-emitting components in optical communication with an interior of the least one fluid-flow passageway.

41. The method of claim 40, wherein selectively energizing includes energetically interrogating a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having a peak emission wavelength ranging from about 100 nanometers to about 400 nanometers.

42. The method of claim 40, wherein selectively energizing includes energetically interrogating a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having a peak emission wavelength ranging from about 100 nanometers to about 320 nanometers.

43. The method of claim 40, wherein selectively energizing includes energetically interrogating a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having a peak emission wavelength ranging from about 280 nanometers to about 320 nanometers.

44. The method of claim 40, wherein selectively energizing includes energizing a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having an operational fluence of the one or more energy emitters is less than about 80 milli-joules per square centimeter.

45. The method of claim 40, wherein selectively energizing includes energizing a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having an operational fluence of less than about 35 milli-joules per square centimeter.

46. The method of claim 40, wherein selectively energizing includes energizing a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having an operational fluence of less than about 15 milli-joules per square centimeter.

47. The method of claim 40, wherein selectively energizing includes energizing a cerebrospinal fluid received within the one or more regions of the at least one fluid-flow passageway with an energy stimulus having an average energy density′

ranging from about less than about 15 milli-joules per square centimeter to about less than about 80 milli-joules per square centimeter.

48. The method of claim 40, further comprising:

delivering an active agent composition to an interior of at least one fluid-flow passageway of an indwelling implant cerebrospinal fluid management system via one or more active agent assemblies in fluidic communication with the interior of the least one fluid-flow passageway.